We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > OBI

News List

OBI Pharma Granted Orphan Drug Designation for ADC Targeted Cancer Therapy americanpharmaceuticalreview
January 06, 2020
OBI Pharma announced the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation for OBI-999 for the treatment of Pancreatic Cancer. OBI-999 is a first-in-class antibody drug conjugate targeting Globo H, a glycolipid antigen.
US FDA grants ODD for OBI Pharma’s OBI-888 to treat pancreatic cancer pharmaceutical-technology
November 29, 2018
Taiwan, Chinaese biopharma company OBI Pharma has received Orphan Drug Designation (ODD) from the US Food and Drug Administration (FDA) for OBI-888 to treat pancreatic cancer patients......
OBI Pharma receives FDA ODD for OBI-3424 biospectrumasia
September 29, 2018
OBI-3424 is a first in class DNA alkylating cancer therapeutic agent targeting aldo-keto reductase 1C3 (AKR1C3) overexpressing cancers.